The Summer issue of Drug Discovery World (DDW) is out now! The DDW Summer issue is out now and looks at where the global biotech hubs are for drug discovery and development, asks how 3D genomics can accelerate personalised medicine, and looks at the technological advances in mass spectrometry. It also includes an exclusive global cancer research guide examining the innovation happening in this sector. Other features in the Summer issue include: - How AI can advance the hit-to-lead process - GSK’s efforts in the autoimmune sector - Improving viral vector safety for cell & gene therapy Read the digital version here: https://lnkd.in/eEiBFnsz #DrugDiscovery #DrugDevelopment #LifeSciences
Drug Discovery World
Book and Periodical Publishing
The Global Business Review of Drug Discovery and Development
About us
Welcome to our LinkedIn page. This is where we will share original content from the DDW team and industry experts, as well as daily news and other company updates. Published for over 20 years, DDW is the only truly global business review of all aspects of drug discovery and development and has firmly established itself as a highly respected and ‘must read’ journal within the discovery and development arena. DDW is renowned for voicing the opinions of some of the Industry’s leading luminaries and has become a recognised ‘platform’ for ‘Industry Gurus’ to discuss and encourage debate on some of the more challenging issues surrounding the technological, strategic and business facets of the pharma and biopharmaceutical industry. DDW has always adhered to the maxim….’Turning Science into Business’. DDW examines the advances in new science and technology with a view to the commercial implications of implementing those advances and whether they can truly bring benefits to the drug discovery and development process with the goal of reducing costs and attrition rates whilst ultimately, bringing new and effective therapeutics to the market faster. DDW is distinguishable in that it reaches out to a global audience at both bench and boardroom level allowing them to understand the new technologies and strategies and the impact they can have on their particular segments of the business. Scientist and CEO alike can profit from the uncomplicated style of the editorial and, furthermore, gain a wealth of information on a diverse range of life science topics. In our articles, we challenge the industry to look at new ways of overcoming discovery bottlenecks, embrace new technologies, form relationships with discovery partners and build next generation technology platforms.
- Website
-
https://www.ddw-online.com/
External link for Drug Discovery World
- Industry
- Book and Periodical Publishing
- Company size
- 2-10 employees
- Headquarters
- London
- Type
- Privately Held
- Founded
- 2000
- Specialties
- Drug Discovery, Pharmaceuticals, Publishing, Biotechnology, and Biopharmaceutical
Locations
-
Primary
London, GB
Employees at Drug Discovery World
Updates
-
Unlocking AI’s potential in drug discovery: A roadmap to scalable solutions Dr Mutlu Dogruel, Vice President of AI Solutions at Cresset examines AI’s transformative potential, highlights the current challenges and introduces a series of potential solutions to implement AI in the drug discovery landscape successfully. https://lnkd.in/ef-SJTWB #AI #DrugDiscovery #ArtificialIntelligence
-
Study offers possible treatment for frontotemporal dementia Vesper Bio has completed a Phase I study for its lead candidate, VES001, a potentially disease-modifying treatment for frontotemporal dementia patients with mutations in the progranulin gene (FTD(GRN)). https://lnkd.in/edn8mBgj #Dementia #Genetics #DrugDiscovery
-
mPTP Inhibitors block mitochondrial dysfunction in ALS NRG Therapeutics has been awarded a non-dilutive grant from TARGET ALS FOUNDATION, INC to support its discovery programme for amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig’s disease or motor neurone disease. https://lnkd.in/e36YjZXj #ALS #Funding #DrugDiscovery
-
CAR-T and orthogonal IL-2 therapy for lupus fast-tracked by FDA https://lnkd.in/eeKgSaj8 #Lupus #AutoimmuneaDisease #CellTherapy
-
AD | We are delighted to share with you that ELRIG UK's Drug Discovery 2024 conference is hosting two fantastic Keynote Speakers: Ijeoma Uchegbu FMedSci, Professor of Pharmaceutical Nanoscience at UCL, and Marcus Schindler, EVP for Research & Early Development and CSO at Novo Nordisk. Discover their insights and register for this free-to-attend event here https://lnkd.in/eBdMJNhU. Join us at ExCeL London on October 2-3 for Europe’s premier Drug Discovery event, featuring 14 science tracks, 100+ speakers, 200 exhibitors, and 2000 delegates. Also, check the agenda for headlines from the Breakthrough Zone, Tech Theatre, Learning Zone and more! Don’t miss out—register now and be part of the innovation! #DrugDiscovery2024 #LifeSciences #Networking #ELRIG MSD GSK AstraZeneca SRG
-
Have you registered for Monday's webinar?
Next-gen antibody discovery: Leveraging DNA immunisation and single B-cell cloning for high-affinity & specificity rabbit mAbs Mon, Sep 9, 2024 3:00 PM - 4:00 PM BST Register for FREE today! https://lnkd.in/e3xKncwV Supported by Fujifilm Wako #DNA #mAbs #DrugDiscovery
-
Cell-Based High-Throughput Screening In the tenth eBook of the Hamilton series, "Cell-Based High-Throughput Screening", we discuss: - Cell-based models used in research – Pros and Cons. - Challenges of cell-based high-throughput screening. - Hamilton software and hardware tools for cell-based assays. Download eBook https://lnkd.in/ev__Dc6M Brought to you by Hamilton Company #InVitro #HighThroughputScreening #Research
-
Eli Lilly and Company and HAYA Therapeutics collaborate to find genome targets for obesity https://lnkd.in/e4NnAGPb #Obesity #Genomics #Genetics
-
Orphan drug prevents cell death in acute liver failure Biotechnology company SeaBeLife Biotech has secured orphan drug designation (ODD) from the European Medicines Agency (EMA) for its drug candidate SBL01 in the treatment of acute liver failure (ALF). https://lnkd.in/eJ-ndD9j #OrphanDrug #AcuteLiverFailure #ALF